Log in
Enquire now
Lenire

Lenire

Lenire is an evidence-based tinnitus treatment from Neuromod, based on the science of neuromodulation.

OverviewStructured DataIssuesContributors

Contents

lenire.com
Is a
Product
Product

Product attributes

Industry
Medical device
Medical device
Healthcare
Healthcare
Launch Date
2015
Founder
‌
Ross O'Neill
Product Parent Company
Neuromod
Neuromod

Other attributes

Full Address
Neuromod Devices Ltd, Rainsford Street, Dublin, D08 R2YP, Ireland
Location
United Kingdom
United Kingdom
Phone Number

Lenire is an evidence-based tinnitus treatment developed and released in the UK by Neuromod in 2015. It is a non-invasive at-home medical device treatment method for chronic and persistent tinnitus (ringing in the ears). A clinician must prescribe Lenire, and treatment requires monitoring over a three-month time period as adjustments may be needed to optimize device effectiveness. A standard course of Lenire treatment lasts for 30 minutes and is used daily.

Case Study

A clinical trial of Lenire was conducted at the St James’s Hospital in Dublin and the Tinnituszentrum of the University Regensburg, Germany, from 2016-2019 and had 326 participants. The study results showed that approximately 86% of treatment-compliant patients reported tinnitus symptom improvement over a 12-week period, and approximately 80% of treatment-compliant patients reported improvement over a 12-month time period.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Lenire

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Pricing
  • Become an Editor
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us

Explore companies

  • Artificial Intelligence
  • Fintech
  • Biotechnology
  • Cybersecurity
  • Semiconductors
  • Electric Vehicles
  • Cloud Computing
  • Robotics
  • SaaS
  • Renewable Energy
  • Venture Capital
  • Blockchain
  • Browse all →
By using this site, you agree to our Terms of Service.